You are on page 1of 19

Who We Are

Biosensors develops, manufactures and markets innovative medical devices for interventional cardiology and critical care procedures.

Performance

Risk Assessment

Conclusion

Our Milestones
1990 2005 2007 2008 2010 2011 Company Founded Listed on SGX Mainboard Acquired 50% interest in JWMS Received CE Mark for BioMatrix Launched in Europe and Asia Hony Capital acquired majority stake in Biosesor Raised S$200 million (Alantis & Ever Union) Fully acquired JWMS

Performance

Risk Assessment

Conclusion

Our Presence

More about us
Market Capitalisation: S$2.25 billion Major shareholders:

Shandong Weigao Hony Capital Fidelity Atlantis EverUnion

Total shares issued: 1.717 billion shares


Performance Risk Assessment Conclusion

Management Team
Yoh Chie Lu, founder and Chairman
President of Asia-Pacific division for BOC

Jeffrey Jump & Jack Wang, Co-CEO


Over 30 years experience

John E. Shulze, Chief Technical Officer


Primary architect of BioMatrix

Ronald H. Ede, Chief Financial Officer


Performance Risk Assessment Conclusion

Growing DES Industry


Vascular Interventional Devices Market
DES

76%

Others

Source: Peripheral Vascular & Interventional Cardiology Devices Market (2011 2016) Global Trends & Competitive Analysis Report Code: MD 1752

Introduction

Risk Assessment

Conclusion

Growing DES Industry


Revenue Generated for Global DES Market (US$ Billion)
13.7 15 10 5 0 2011 2016
Source: Peripheral Vascular & Interventional Cardiology Devices Market (2011 2016) Global Trends & Competitive Analysis Report Code: MD 1752

8.9

Introduction

Risk Assessment

Conclusion

Our Business Model


Sales and Marketing Expenses Research and Development (R&D) General and Administrative Expenses Other operating expenses Introduction Risk Assessment Conclusion

Abluminal Coating Biolimus A9

S-Stent Platform Biodegradable Polymer

Competitive Edge
The First Biodegradable DES - BioMatrix Strong clinical trial results Access to Chinas emerging market JWMS Next generation of DES- BioFreedom Strategic acquisition for technology development CardioMind Inc. AXXESSTM (Devax, Inc.)
Introduction Risk Assessment Conclusion

Financial Highlights
Revenue EPS

34.79%
Profit ROE

32.60%

34.98%
Introduction

48.42%
Risk Assessment Conclusion

Liquidity: High
GEARING RATIO COMPARISON
60 50 40 30 20 10 0 2009 BIOSENSORS 2010 BOSTON SCIENTIFIC 2011 MEDTRONIC 20.18 9.08 45.19 48.11 48.11 48.14 48.14 37.53 37.53 6.00 5.00 4.00 3.00 2.07 2.00 1.00 0.00 2009 BIOSENSORS 2010 BOSTON SCIENTIFIC 2011 MEDTRONIC 1.06 1.52 2.17 1.39 2.37 1.72

CURRENT RATIO COMPARISON


5.35

1.92

Introduction

Risk Assessment

Conclusion

ROE Comparison
ROE COMPARISON
25.00% 21.11% 20.00% 15.70% 15.00% 11.43% 10.00% 5.00% 0.00% -1.08% -5.00% -10.00% -15.00% BIOSENSORS BOSTON SCIENTIFIC MEDTRONIC -8.66% 2009 2010 2011 3.88% 2.16% 19.39%

-9.07%

Introduction

Risk Assessment

Conclusion

Profitability and Efficiency


ASSET TURNOVER RATIO COMPARISON
0.7000 0.6000 0.5000 0.4000 0.3000 0.2000 0.1000 0.0000 2009 BIOSENSORS 2010 BOSTON SCIENTIFIC 2011 MEDTRONIC 0.3252 0.3528 0.3580 0.3276 0.5993 0.6189 0.5101 0.5631 0.5237

NET PROFIT MARGIN COMPARISON


30.00% 25.00% 20.00% 15.00% 10.00% 5.00% 0.00% -5.00% -10.00% -15.00% -20.00% -13.01% -13.13% BOSTON SCIENTIFIC MEDTRONIC -0.94% 2009 2010 2011 14.18% 5.79% 27.59% 19.59% 27.63% 19.43%

BIOSENSORS

Introduction

Risk Assessment

Conclusion

Growth Strategy
Expanding in China JW Medical Service Growing market Penetrating the United States Largest global DES market Expanding Product Portfolio

Introduction

Risk Assessment

Conclusion

Risk Assessment
Preferred supplier agreements Declining prices of DES Competition from local manufacturers Regulatory Requirement

Introduction

Performance

Conclusion

3 Reasons to Invest
We make dollars and stents Every 2 seconds someone has a heart attack Access to growing markets

Introduction

Performance

Q&A

You might also like